Seroprevalence of Measles, Mumps, Rubella, and Varicella-Zoster Virus Antibodies—United States, 2017–March 2020
The Journal of Infectious Diseases · 08.07.2026
DOI: 10.1093/infdis/jiag354 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 08.07.2026. Verfasst von Chelsea S Lutz und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. Die Arbeit nennt 33 Literaturangaben. Gefördert von: National Health and Nutrition, Centers for Disease Control and Prevention.
Abstract (Originalsprache)
Background
The most recent assessment of antibodies against measles, mumps, rubella, and varicella-zoster viruses (MeV, MuV, RuV, VZV) in the United States was conducted in 2009–2010. Regular assessments are essential to measure the impact of immunization programs, identify immunity gaps, and inform vaccination strategies. We report updated estimates of national seroprevalence.
Methods
We used a CDC-developed immunoglobulin G multiplex bead assay to quantitatively detect antibodies against MeV, MuV, RuV, and VZV among participants aged 6–59 years in the 2017–March 2020 National Health and Nutrition Examination Survey. We estimated seroprevalence overall and by sociodemographic characteristics and assessed independent predictors of seropositivity using logistic regression models with weighted procedures for complex survey design.
Results
Overall seroprevalence was 95.2% (95% CI, 94.0%–96.3%) against MeV, 87.8% (95% CI, 86.5%–89.2%) against MuV, 95.6% (95% CI, 94.5%–96.5%) against RuV, and 97.2% (95% CI, 96.4%–98.0%) against VZV and remained high across advancing age groups. Younger age and non-Hispanic Black race and ethnicity were independent predictors for MeV, MuV, and RuV seropositivity; sex, birthplace, and health insurance status were independent predictors for seropositivity for at least one of the viruses.
Conclusions
Nationally, seroprevalence for MeV, MuV, RuV, and VZV antibodies remains high among persons aged 6–59 years, and our findings indicate robust antibody responses are maintained decades after vaccination or natural infection. Maintaining high population immunity through vaccination is critical to prevent cases and outbreaks of all 4 vaccine-preventable diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
- U.S. Public Health Service Commissioned Corps, Rockville, MD, USA.
ORCID-Profile: Patricia Castro-Roman, Mona Marin, Stephen N Crooke, Thomas D Filardo, Daniel L Joo, Tatiana M Lanzieri, Eriko Padron-Regalado, David E Sugerman, Jamie Tappe, Tara C Anderson
Förderung
- National Health and Nutrition
- Centers for Disease Control and Prevention
Zitieren
APA
Lutz, C. S., Castro-Roman, P., Marin, M., Wakeman, B., Crooke, S. N., El-Badry, E., Escudero Gonzalez, N. A., Filardo, T. D., Kuang, Z., Joo, D. L., Lanzieri, T. M., Oliver, S. E., Padron-Regalado, E., Sugerman, D. E., Tappe, J., Rota, P. A., & Anderson, T. C. (2026). Seroprevalence of Measles, Mumps, Rubella, and Varicella-Zoster Virus Antibodies—United States, 2017–March 2020. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag354
Vancouver
Lutz CS, Castro-Roman P, Marin M, Wakeman B, Crooke SN, El-Badry E, et al. Seroprevalence of Measles, Mumps, Rubella, and Varicella-Zoster Virus Antibodies—United States, 2017–March 2020. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag354
BibTeX
@article{Lutz2026,
author = {Lutz, Chelsea S and Castro-Roman, Patricia and Marin, Mona and Wakeman, Brian and Crooke, Stephen N and El-Badry, Elina and Escudero Gonzalez, Nicole A and Filardo, Thomas D and Kuang, Zhizhou and Joo, Daniel L and Lanzieri, Tatiana M and Oliver, Sara E and Padron-Regalado, Eriko and Sugerman, David E and Tappe, Jamie and Rota, Paul A and Anderson, Tara C},
title = {Seroprevalence of Measles, Mumps, Rubella, and Varicella-Zoster Virus Antibodies—United States, 2017–March 2020},
journal = {The Journal of Infectious Diseases},
year = {2026},
doi = {10.1093/infdis/jiag354}
}
EUVIMED